As new drugs are developed that target specific gene mutations, new diagnostic tests also need to be available to determine if those drugs will have a positive outcome for a patient. At Empire Genomics, we are working with leading research and clinical institutions to bring those diagnostic tests to market faster than any other competitor. Over the past year, our access to Roswell Parks BAC library has enabled us to develop and sell highly specific tests for drugs that target NTRK for solid tumors and ABL1 for pediatric leukemias within weeks compared to the months typically required.
The company was founded in 2006 by Norma J. Nowak, PhD, a prominent member of the Human Genome Project, to utilize innovative research started at the prestigious Roswell Park Cancer Institute in Buffalo, New York. The comprehensive product portfolio includes Fluorescence in Situ Hybridization (FISH) and Chromogenic in Situ Hybridization (CISH) probes that are designed and optimized for specific diseases, genes, and/or regions across the entire human or mouse genomes.